AlphAIalphai — Financial news for AI agents
finance.yahoo.comAUG 311 min read$CRMD

CorMedix (CRMD) Upgraded to Buy: Here's Why

CorMedix (CRMD) was upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates, which often impacts stock prices. The Zacks rating system tracks consensus EPS estimates, and upgrades typically signal a positive earnings outlook, potentially boosting the stock price.

Original reporting
finance.yahoo.com
Published Aug 31, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 31, 2026, 5:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$CRMD
Bullish
medium confidence
Mentioned
$CRMD
Relevance
5/10
alphai data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$CRMDBullishLow
01

Why it matters

Analyst upgrade signals improved earnings outlook, potentially prompting buying pressure.

02

Market read

The upgrade may attract short‑term interest in CRMD, but lacks hard financial data.

03

What to watch

No concrete earnings numbers released; upgrade relies on analyst consensus.

Relevance 5/10Novelty 5/10Timing: recent upgrade

Background

Zacks Rank upgrades are driven by changes in consensus EPS estimates.

Company-level read

Ticker impact

$CRMDBullishMedium confidence
Context

Zacks upgraded CorMedix (CRMD) to Rank #2 (Buy) after earnings estimate revisions.

Expected impact

Potential short‑term rally as investors adjust valuations.

Evidence & confidence

Upgrade is based on rising EPS estimates, a known driver of price moves.

Market effects

Sector

May lift sentiment in the biotech/health‑tech sector.

Regional

Limited to US small‑cap investors.

Global

Minimal global impact.

Counterpoint

What could challenge this read

Upgrade could be premature if earnings estimates revert.

Key entities

  • company
    CorMedix

    Biotech firm focused on clinical trial data analytics.

  • analyst
    Zacks Investment Research

    Provider of the Zacks Rank rating system.

Read at source← All news

Related articles

AUG 20
$CRMDMedAI 8/10

CorMedix (CRMD) Q2 2026 Earnings Call Transcript

CorMedix (CRMD) reported Q2 2026 revenue of $101.9M and adjusted EBITDA of $58.7M. The company signed a commercial supply agreement for DefenCath with a large dialysis organization, covering all top U.S. providers. Full-year revenue guidance was reaffirmed at $325M-$345M, while adjusted EBITDA guidance was raised to $125M-$140M. CorMedix anticipates submitting an sNDA for REZZAYO in Q3 2026, with potential FDA action in H1 2027. The company plans to invest in commercial infrastructure for a pote

yahoo.com2 min
AUG 15
$CRMDMed

CorMedix Inc. Q2 2026 Earnings Call Summary

CorMedix reported Q2 2026 progress on DefenCath and its REZZAYO pipeline. The company secured a multi-year supply agreement covering all leading U.S. dialysis providers, maintained DefenCath utilization through the TDAPA transition, and raised 2026 adjusted EBITDA guidance to $125-$140 million. It plans a REZZAYO prophylaxis sNDA submission in Q3 2026, with FDA action expected in H1 2027.

yahoo.com7 min
AUG 14
$CRMDMed

CorMedix Q2 Earnings Call Highlights

CorMedix (NASDAQ:CRMD) reported Q2 revenue rising to $39.7M from $39.7M a year earlier, with 2026 including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M ($0.33 basic). It reaffirmed 2026 revenue guidance of $325M-$345M and raised adjusted EBITDA to $125M-$140M. REZZAYO supplemental NDA is planned for Q3 2026, with FDA action expected H1 2027.

yahoo.com6 min
AUG 13
$CRMDMedAI 8/10

CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

CorMedix Therapeutics (Nasdaq: CRMD) reported Q2 2026 consolidated revenue of $101.9M, including $66.1M DefenCath sales and $35.8M from the Melinta portfolio. Net income was $26.0M and adjusted EBITDA $58.7M. The company maintained FY2026 revenue guidance at $325M-$345M and raised adjusted EBITDA to $125M-$140M, with a REZZAYO sNDA FDA submission expected in Q3 2026.

finanznachrichten.de6 min
AUG 13
$CRMDHigh

CorMedix Inc. (CRMD): Results of Operations and Financial Condition

CorMedix Inc. (CRMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CORMEDIX THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE ‒ Q2 2026 Consolidated Revenue of $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Rais

SEC EDGAR 8-K7 min